Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345258 | 0.87 | CYP2D6 (0.39) | CYP2D6 | |
| SCHEMBL23344765 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4E | |
| SCHEMBL24597264 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL23345230 | 0.75 | CYP4F2 (0.40) | SMN1; SMN2CYP2D6 | |
| SCHEMBL23344999 | 0.74 | CYP1A2 (0.39) | SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL23995691 | 0.74 | CHRNB2 (0.43) | SMN1; SMN2 | |
| SCHEMBL19014335 | 0.73 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4E | |
| SCHEMBL23995666 | 0.72 | CYP1A2 (0.38) | SMN1; SMN2CYP2D6 | |
| SCHEMBL18711508 | 0.69 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL18711885 | 0.68 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | SMN1; SMN2 375/4885CYP2D6 1512/4885KDM4E 4779/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | SMN1; SMN2 432/4885CYP2D6 1282/4885KDM4E 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.